Page 2 - Adagene News Today

Adagene Inc. (NASDAQ:ADAG – Get Rating) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 111,400 shares, an increase of 17.8% from the October 31st total of 94,600 shares. Based on an average daily trading volume, of 55,800 shares, the short-interest ratio is […]

Adagene (NASDAQ:ADAG – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene Inc. is based […]

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab - ADG126-P001... | March 16, 2022

Sanofi seems to be in a betting mood and has been picking up card after card in licensing deals to bulk up its early-stage pipeline.

Legend Biotech's Johnson & Johnson-partnered CAR-T therapy Carvykti won an FDA go-ahead to challenge Bristol Myers Squibb's Abecma in multiple myeloma.

- Total potential transaction value of $2.5 billion plus royalties -    SAN DIEGO and SUZHOU, China, March 02, 2022 -- Adagene Inc. , a company transforming the discovery and... | March 2, 2022

SAN DIEGO and SUZHOU, China, Jan. 27, 2022 -- Adagene Inc. , a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been... | January 27, 2022

- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision...

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with...